Theranostics : Impact Factor & More
eISSN: 1838-7640pISSN: 1838-7640
Open AccessShare this on:
Key Metrics
CiteScore 
16.7
Impact Factor
10 - 15
Scite Index
0.93 5-Year SI
SJR
Q1Medicine (miscellaneous)
SNIP
1.75
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Theranostics
Theranostics Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | IVYSPRING INT PUBL |
| Language | English |
| Frequency | Irregular |
| Article Processing Charges | AUD 2500 |
| Publication Time | 12 |
| Editorial Review Process | Peer review |
| General Details | |
| Language | English |
| Frequency | Irregular |
| Publication Start Year | 2011 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors |
View less
Planning to publish in Theranostics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Theranostics
Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1)
- 9 Apr 2026
- Theranostics
Biomaterials in pancreatic surgery: progress and challenges in preoperative, intraoperative and postoperative care
- 3 Apr 2026
- Theranostics
Specific imaging of bacterial infection: a translational approach using positron emission tomography and gallium-68-labeled maltohexaose
- 30 Mar 2026
- Theranostics
One-step knock-in CAR constructs in human NK cells enable scalable, TGFβ1-resistant immunotherapy for solid tumors.
- 25 Mar 2026
- Theranostics
From bench to bedside: the promise and roadblocks of extracellular vesicle therapeutics.
- 26 Feb 2026
- Theranostics
Macrophage membrane-functionalized nanotherapeutics for tumor targeted therapy: Erratum
- 20 Feb 2026
- Theranostics
Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1)
- 9 Apr 2026
- Theranostics
Biomaterials in pancreatic surgery: progress and challenges in preoperative, intraoperative and postoperative care
- 3 Apr 2026
- Theranostics
Specific imaging of bacterial infection: a translational approach using positron emission tomography and gallium-68-labeled maltohexaose
- 30 Mar 2026
- Theranostics
One-step knock-in CAR constructs in human NK cells enable scalable, TGFβ1-resistant immunotherapy for solid tumors.
- 25 Mar 2026
- Theranostics
From bench to bedside: the promise and roadblocks of extracellular vesicle therapeutics.
- 26 Feb 2026
- Theranostics
Macrophage membrane-functionalized nanotherapeutics for tumor targeted therapy: Erratum
- 20 Feb 2026
- Theranostics
FAQs on Theranostics
How long has Theranostics been actively publishing? 
What is the publishing frequency of Theranostics?
How many articles did Theranostics publish last year?
What is the eISSN & pISSN for Theranostics?
What is Citescore for Theranostics?
What is SNIP score for Theranostics?
What is the SJR for Theranostics?
Who is the publisher of Theranostics?
